Publications​

Molekulare Klassifikation des Harnblasenkarzinoms – Mögliche Ähnlichkeit zum Mammakarzinom

RM Wirtz, V Fritz, R Stöhr, A Hartmann
Der Pathologe, February 2016, Volume 37, Issue 1, pp 52-60

ESR1, ERBB2, and Ki67 mRNA expression predicts stage and grade of non-muscle-invasive bladder carcinoma (NMIBC).

J Breyer, RM Wirtz, M Laible, K Schlombs, P Erben, MC Kriegmair, R Stoehr, S Eidt, S Denzinger, M Burger, A Hartmann, W Otto
Virchows Arch, August 2016

Expression of the p53 Inhibitors MDM2 and MDM4 as Outcome Predictor in Muscle-invasive Bladder Cancer

Kriegmair MC, Balk M, Wirtz R, Steidler A, Weis CA, Breyer J, Hartmann A, Bolenz C, Erben P
Anticancer Res, October 2016, Volume 36, Issue 10, pp 5205-5213

ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ

Breyer J, Otto W, Wirtz RM, Wullich B, Keck B, Erben P, Kriegmair MC, Stoehr R, Eckstein M, Laible M, Schlombs K, Eidt S, Denzinger S, Burger M, Hartmann A
Urol Int, 2017;98(3):282-289

In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival

Breyer J, Wirtz RM, Otto W, Erben P, Kriegmair MC, Stoehr R, Eckstein M, Eidt S, Denzinger S, Burger M, Hartmann A
Virchows Arch, 2017 Mar;470(3):267-274

High androgen receptor mRNA expression is independently associated with prolonged cancer-specific and recurrence-free survival in stage T1 bladder cancer

Sikic D, Breyer J, Hartmann A, Burger M, Erben P, Denzinger S, Eckstein M, Stoehr R, Wach S, Wullich B, Keck B, Wirtz RM, Otto W
Trans Oncol, 2017 Jun;10(3):340-345

Predictive value of molecular subtyping in NMIBC by RT-qPCR of ERBB2, ESR1, PGR and MKI67 from formalin-fixed TUR biopsies.

Breyer J, Wirtz RM, Otto W, Laible M, Schlombs K, Erben P, Kriegmair MC, Stoehr R, Eidt S, Denzinger S, Burger M, Hartmann A
Oncotarget, 2017 Jun 28

High CDKN2A/p16 and low FGFR3 expression predict progressive potential of stage pT1 urothelial bladder carcinoma

Breyer J, Wirtz RM, Erben P, Worst TS, Stoehr R, Eckstein M, Bertz S, Sikic D, Denzinger S, Burger M, Hartmann A, Otto W, BRIDGE Consortium e.V. Mannheim
Clin Genitourin Cancer, 2018.

A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy.

Eckstein M, Wirtz RM, Pfannstil C, Wach S, Stoehr R, Breyer J, Erlmeier F, Günes C, Nitschke K, Weichert W, Otto W, Keck B, Eidt S, Burger M, Taubert H, Wullich B, Bolenz C, Hartmann A, Erben P
Oncotarget, 2018 Feb 19;9(19):15001-15014.

High PDL1mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients

Breyer J, Wirtz RM, Otto W, Erben P, Worst TS, Stoehr R, Eckstein M, Denzinger S, Burger M, Hartmann A
Cancer Immunol Immunother, 2018 Mar;67(3):403-412.

Prognostic Value of molecular breast cancer subtypes based on Her2, PGR and Ki67 mRNA-Expression in muscle invasive bladder cancer

Kriegmair MC, Wirtz RM, Worst TS, Breyer J, Ritter M, Keck B, Boehmer C, Otto W, Eckstein M, Weis CA, Hartmann A, Bolenz C, Erben P
Transl Oncol, 2018 Apr;11(2):467-476

CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making.

Worst TS, Weis CA, Stöhr R, Bertz S, Eckstein M, Otto W, Breyer J, Hartmann A, Bolenz C, Wirtz RM, Erben P.

Sci Rep. 2018 Sep 26;8(1):14383. doi: 10.1038/s41598-018-32569-x.

FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer.

Breyer J, Wirtz RM, Erben P, Rinaldetti S, Worst TS, Stoehr R, Eckstein M, Sikic D, Denzinger S, Burger M, Hartmann A, Otto W.

BJU Int. 2019 Jan;123(1):187-196. doi: 10.1111/bju.14525. Epub 2018 Sep 9.

FOXM1 predicts disease progression in non-muscle invasive bladder cancer.

Rinaldetti S, Wirtz R, Worst TS, Hartmann A, Breyer J, Dyrskjot L, Erben P. J Cancer Res Clin Oncol. 2018 Sep;144(9):1701-1709. doi: 10.1007/s00432-018-2694-5. Epub 2018 Jun 29.

The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes.

Pfannstiel C, Strissel PL, Chiappinelli KB, Sikic D, Wach S, Wirtz RM, Wullweber A, Taubert H, Breyer J, Otto W, Worst T, Burger M, Wullich B, Bolenz C, Fuhrich N, Geppert CI, Weyerer V, Stoehr R, Bertz S, Keck B, Erlmeier F, Erben P, Hartmann A, Strick R, Eckstein M; BRIDGE Consortium, Germany;  Cancer Immunol Res. 2019 Jun;7(6):923-938. doi: 10.1158/2326-6066.CIR-18-0758. Epub 2019 Apr 15.

Androgen Receptor mRNA Expression in Urothelial Carcinoma of the Bladder: A Retrospective Analysis of Two Independent Cohorts.

Sikic D, Wirtz RM, Wach S, Dyrskjøt L, Erben P, Bolenz C, Breyer J, Otto W, Hoadley KA, Lerner SP, Eckstein M, Hartmann A, Keck B. Transl Oncol. 2019 Apr;12(4):661-668. doi: 10.1016/j.tranon.2019.01.005. Epub 2019 Mar 2.

Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.

Eckstein M, Erben P, Kriegmair MC, Worst TS, Weiß CA, Wirtz RM, Wach S, Stoehr R, Sikic D, Geppert CI, Weyerer V, Bertz S, Breyer J, Otto W, Keck B, Burger M, Taubert H, Weichert W, Wullich B, Bolenz C, Hartmann A, Erlmeier F.

Eur J Cancer. 2019 Jan;106:234-243. doi: 10.1016/j.ejca.2018.11.007. Epub 2018 Dec 5.

Analysis of the prognostic relevance of sex-steroid hormonal receptor mRNA expression in muscle-invasive urothelial carcinoma of the urinary bladder.

Erben P, Sikic D, Wirtz RM, Martini T, Weis CA, Breyer J, Otto W, Keck B, Hartmann A, Bolenz C; BRIDGE Consortium e.V.

Virchows Arch. 2019 Feb;474(2):209-217. doi: 10.1007/s00428-018-2496-9. Epub 2018 Nov 27.

Predictive value of lymphangiogenesis and proliferation markers on mRNA level in urothelial carcinoma of the bladder after radical cystectomy.

Martini T, Heinkele J, Mayr R, Weis CA, Wezel F, Wahby S, Eckstein M, Schnöller T, Breyer J, Wirtz R, Ritter M, Bolenz C, Erben P.

Urol Oncol. 2018 Dec;36(12):530.e19-530.e27. doi: 10.1016/j.urolonc.2018.09.003. Epub 2018 Nov 13.

mRNA-Expression of KRT5 and KRT20 Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological Variants.

Eckstein M, Wirtz RM, Gross-Weege M, Breyer J, Otto W, Stoehr R, Sikic D, Keck B, Eidt S, Burger M, Bolenz C, Nitschke K, Porubsky S, Hartmann A, Erben P.

Int J Mol Sci. 2018 Oct 30;19(11). pii: E3396. doi: 10.3390/ijms19113396.

Four Tumour Markers for Urinary Bladder Cancer – Tissue Polypeptide Antigen (TPA), HER-2/neu (ERB B2), Urokinase-type Plasminogen Activator Receptor (uPAR) and TP53 Mutation.

Ecke TH, Schlechte HH, Schulze G, Lenk SV, Loening SA.

Anticancer Res 2005; 25(1B):635-642.

Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium.

Ecke TH, Bartel P, Koch S, Ruttloff J, Theissig F.

Oncol Rep 2006; 16(6): 1381-1388.

Tumour Markers for Urinary Bladder Cancer: Chances for daily routine.

Ecke TH.

J Lab Med 2010; 34(2): 77-86.

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical and Gastric Cancers.

Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, Bonfrer J, Ecke TH, Grossman HB, Hayes P, Hoffmann RT, Lerner SP, Löhe F, Louhimo J, Sawczuk I, Taketa K, Diamandis EP. Clin Chem 2010; 56(6): e1-48.

KISS1 Methylation and Expression as Tumor Stratification Biomarkers and Clinical Outcome Prognosticators for Bladder Cancer Patients.

Cebrian V, Fierro M, Orenes-Piñero E, Grau L, Moya P, Ecke T, Alvarez M, Gil M, Algaba F, Bellmunt J, Cordon-Cardo C, Catto J, López-Beltrán A, Sánchez-Carbayo M.

Am J Pathol  2011; 179(2): 540-546.

The Impact of Gender on Outcomes in Patients With Metastatic Urothelial Carcinoma.

Haines L, Bamias A, Krege S, Lin CC, Hahn N, Ecke TH, Moshier E, Sonpavde G, Godbold J, Oh WK, Galsky MD.

Clin Genitourin Cancer. 2013; 11(3): 346-52.

Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy.

Galsky MD, Moshier E, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Godbold J, Oh WK, Bamias A.

Cancer. 2013; 119(16): 3012-9.

Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer.

Galsky MD, Krege S, Lin CC, Hahn N, Ecke TH, Moshier E, Sonpavde G, Godbold J, Oh WK, Bamias A. Urol Oncol 2014; 32: 15-21.

Biomarker in Cisplatin-Based Chemotherapy for Urinary Bladder Cancer.

Ecke TH.

Adv Exp Med Biol. 2015; 867: 293-316.

Obesity and Outcomes in Patients with Metastatic Urothelial Carcinoma.

Leiter A, Doucette J, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Bamias A, Oh WK, Galsky MD.

Bladder Cancer 2016; 2: 341–349.

UBC® Rapid Test for detection of carcinoma in situ for bladder cancer.  Ecke TH, Weiß S, Stephan C, Hallmann S, Barski D, Otto T, Gerullis H. Tumor Biol. 2017 May; 39(5): X

miR- 199a- 3p and miR- 214- 3p improve the overall survival prediction of muscle- invasive bladder cancer patients after radical cystectomy.  Ecke TH, Stier K, Weickmann S, Zhao Z, Buckendahl L, Stephan C, Kilic E, Jung K.

Cancer Med 2017 Sep 5; 1-11.

Immunological tumor status may predict response to neoadjuvant chemotherapy and outcome after radical cystectomy in bladder cancer.

Tervahartiala M, Taimen P, Mirtti T, Koskinen I, Ecke T, Jalkanen S, Boström PJ.

Sci Rep 2017; 7: 12682.

Evaluation of a New Survivin ELISA and UBC® Rapid for the Detection of Bladder Cancer in Urine.

Gleichenhagen J, Arndt C, Casjens S, Meinig C, Gerullis H, Raiko I, Brüning T, Ecke T, Johnen G.

Int J Mol Sci. 2018 Jan 11; 19(1).

Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network.

Zuiverloon TCM, van Kessel KEM, Bivalacqua TJ, Boormans JL, Ecke TH, Grivas PD, Kiltie AE, Liedberg F, Necchi A, van Rhijn BW, Roghmann F, Sanchez-Carbayo M, Schmitz-Dräger BJ, Wezel F, Kamat AM.

Urol Oncol. 2018 Feb 26. pii: S1078-1439(18)30036-X. doi: 10.1016/j.urolonc.2018.01.014.

Diagnostic and Prognostic Potential of MicroRNA Maturation Regulators Drosha, AGO1 and AGO2 in Urothelial Carcinomas of the Bladder.

Rabien A, Ratert N, Högner A, Erbersdobler A, Jung K, Ecke TH*, Kilic E*. Int J Mol Sci. 2018 May 31;19(6). pii: E1622. doi: 10.3390/ijms19061622.

UBC® Rapid Test—A Urinary Point-of-Care (POC) Assay for Diagnosis of Bladder Cancer with a focus on Non-Muscle Invasive High-Grade Tumors: Results of a Multicenter-Study.

Ecke TH, Weiß S, Stephan C, Hallmann S, Arndt C, Barski D, Otto T, Gerullis H. Int. J. Mol. Sci. 2018, 19(12), 3841.

Molecular identification of telomerase reverse transcriptase (TERT) promotor mutations in primary and recurrent tumors of invasive and noninvasive urothelial bladder cancer.

Roggisch J, Ecke T*, Koch S*.

Urol Oncol. 2019 Sep 11. pii: S1078-1439(19)30325-4. doi: 10.1016/j.urolonc.2019.08.007.

Validation of a novel, sensitive and specific urine-based test for recurrence surveillance of patients with non-muscle invasive bladder cancer in a comprehensive multicenter study.

Batista R, Vinagre J, Prazeres H, Sampaio C, Peralta P, Conceição P, Sismeiro A, Leão R, Gomes A, Almeida F, Romero Gonzalez E, Bidovanets B, Ecke T, Stijns P, Minnee P, Serrano A, Abdelmalek R, Villafruela A, Beardo-Villar P, Fidalgo N, Öztürk H, Garranzo M, Monzo J, Lopes T, Martínez-Piñeiro L, Parra Servan P, Moreno Perez De La Cruz S, Bolono Del Pozo A, Pual Sanchez Perez M, Máximo V, Soares P. Front Genet 2019

Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation.

Morsch R, Rose M, Maurer A, Cassataro MA, Braunschweig T, Knüchel R, Vögeli TA, Ecke T, Eckstein M, Weyerer V, Esposito I, Ackermann M, Niegisch G, Gaisa NT; German Study Group of Bladder Cancer (DFBK e.V.). BMC Cancer. 2020 Mar 18;20(1):230. doi: 10.1186/s12885-020-06727-2.